New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine.

  title={New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine.},
  author={Margot W. Beukers and Lisa C W Chang and Jacobien K. von Frijtag Drabbe K{\"u}nzel and Thea Mulder-Krieger and Ronald F Spanjersberg and Johannes Brussee and Adriaan P. IJzerman},
  journal={Journal of medicinal chemistry},
  volume={47 15},
The adenosine A(2B) receptor is the least well characterized of the four known adenosine receptor subtypes because of the absence of potent, selective agonists. Here, we present five non-adenosine agonists. Among them, 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3,5-dicarbonitrile, 17, LUF5834, is a high-efficacy partial agonist with EC(50) = 12 nM and 45-fold selectivity over the adenosine A(3) receptor but lacking selectivity versus the A(1) and A(2A) subtypes… 
Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors
Recently, high-affinity radioligands for A2B receptors, N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide] ([3H]MRE 2029F20), have been introduced.
Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines.
The synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A1 receptor agonists with tunable binding kinetics are reported, bringing new evidence of the consequences of affinity-only driven selection of drug candidates.
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
A number of 3'-C-methyl analogues of selective adenosine receptor agonists such as CPA, CHA, CCPA, 2'-Me-CCPA, NECA, and IB-MECA was synthesized to further investigate the subdomain of the receptor
A3 Adenosine Receptor Agonists: History and Future Perspectives
The potency and efficacy of various adenosine derivatives at the A3AR also depends on the second messenger system being studied, which has led to a proposed concept of “effect reversal” for this receptor.
ZM 241385 , DPCPX , MRS 1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A 2 B Receptor
This study is the first description of inverse agonists for the human adenosine A2B receptor and the use of receptor mutants with varying levels of constitutive activity enabled us to determine the relative intrinsic efficacy of these inverse agonist compounds.
A Novel Nonribose Agonist, LUF5834, Engages Residues That Are Distinct from Those of Adenosine-Like Ligands to Activate the Adenosine A2a Receptor
The findings suggest that this class of agonist interacts with distinct residues to activate the receptor compared with classic adenosine derived agonists.